Elicio Therapeutics (ELTX) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tevogen (TVGN) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 80.5% versus a loss of 82.8%. Elicio Therapeutics is the larger company by market cap ($47.6 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | TVGN |
|---|---|---|
| Share price | $1.81 | $7.06 |
| Market cap | $47.57M | $45.97M |
| 1-day change | -2.16% | +8.78% |
| YTD return | -77.26% | -57.34% |
| 1-year return | -82.79% | -80.50% |
| 5-year return | -97.92% | — |
| EPS (TTM) | $-2.16 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.00 | $39.00 |
| 52-week low | $1.71 | $3.64 |
| Distance from 52-week high | -88.69% | -81.90% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +655.25% | — |
| Average volume | 340.72K | 10.03K |
| Shares outstanding | 26.28M | 6.51M |
| Employees | 33 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Healthcare · Biotechnology · 18 employees
ELTX vs TVGN FAQ
Which is bigger, Elicio Therapeutics or Tevogen?
Elicio Therapeutics (ELTX) is larger, with a market capitalization of $47.57M compared with $45.97M for Tevogen (TVGN).
Which stock has performed better over the past year, ELTX or TVGN?
TVGN returned -80.50% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.